Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Ordinary Shares, par value CHF 0.10 per share
-
Shares outstanding
-
41.7M
-
Number of holders
-
7
-
Total shares
-
3.12M
-
Shares change
-
+3.12M
-
Total reported value, excl. options
-
$23.2M
-
Value change
-
+$23.2M
-
Number of buys
-
7
-
Price
-
$7.43
Significant Holders of Oculis Holding AG - Ordinary Shares, par value CHF 0.10 per share (OCS) as of Q1 2023
7 filings reported holding OCS - Oculis Holding AG - Ordinary Shares, par value CHF 0.10 per share as of Q1 2023.
Oculis Holding AG - Ordinary Shares, par value CHF 0.10 per share (OCS) has 7 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.12M shares
of 41.7M outstanding shares and own 7.49% of the company stock.
Largest 7 shareholders include Pivotal bioVenture Partners Investment Advisor LLC (2.38M shares), Nan Fung Group Holdings Ltd (651K shares), Compagnie Lombard Odier SCmA (65K shares), HRT FINANCIAL LP (24.6K shares), UBS Group AG (1.21K shares), Elequin Securities, LLC (300 shares), and DUPONT CAPITAL MANAGEMENT CORP (4 shares).
This table shows the top 7 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.